Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10515	Companies
221781	Keywords
150986	Articles
117327	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 09/17/2024 at 17:00, 1 year 8 months ago

Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
Moderna's SPIKEVAX® KP.2 variant COVID-19 vaccine authorized in Canada for 2024-2025 season to protect against COVID-19 strains. Delivery to begin promptly for vaccination campaigns

COVID-19 Vaccine Health Canada Moderna Spikevax Vaccination Campaigns
BRIEF

published on 09/12/2024 at 12:05, 1 year 8 months ago

Moderna R&D Day Highlights Progress and Strategic Priorities

COVID-19 Vaccine Financial Outlook Vaccine Approvals Moderna Updates R&D Strategy
PRESS RELEASE

published on 09/12/2024 at 12:00, 1 year 8 months ago

Moderna R&D Day Highlights Progress and Strategic Priorities
Moderna, Inc. announces program updates focusing on ten product approvals through 2027, submission of next-gen COVID vaccine and flu/COVID combo vaccine in 2024, positive Phase 3 results for RSV vaccine, and cost efficiency improvements

Moderna Vaccine Phase 3 Results Product Approvals R&D Expense Reduction
BRIEF

published on 09/09/2024 at 13:05, 1 year 8 months ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada

Health Canada Moderna MRNA Vaccines Laval Facility Drug Establishment License
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 8 months ago

Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
Moderna's Laval facility in Canada attains Drug Establishment License, a key step towards onshore mRNA vaccine production by 2025. This milestone boosts national vaccine supply

Canada Manufacturing Facility Moderna MRNA Vaccines Drug Establishment License
BRIEF

published on 09/05/2024 at 14:05, 1 year 8 months ago

EMA Recommends Authorization of Moderna's Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

Authorization COVID-19 Vaccine Moderna EMA SARS-CoV-2 Variant
PRESS RELEASE

published on 09/05/2024 at 14:00, 1 year 8 months ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
Moderna's updated COVID-19 mRNA vaccine targeting SARS-CoV-2 variant JN.1 receives positive opinion from CHMP for European Commission authorization decision for 2024-2025 vaccination season

COVID-19 Vaccine European Commission Moderna MRNA Spikevax
BRIEF

published on 09/03/2024 at 14:35, 1 year 9 months ago

Moderna Receives MHRA Authorization for Updated COVID-19 Vaccine Targeting JN.1 Variant

COVID-19 Moderna Vaccine JN.1 Variant MHRA
PRESS RELEASE

published on 09/03/2024 at 14:30, 1 year 9 months ago

Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
MHRA authorizes Moderna's updated COVID-19 vaccine targeting JN.1 variant. Available for NHS and private purchase in the UK. Follows WHO recommendation for JN.1 subvariants

COVID-19 Vaccine Moderna JN.1 Variant MHRA Authorization Private Purchase
BRIEF

published on 09/02/2024 at 13:05, 1 year 9 months ago

Taiwan FDA Approves Moderna’s COVID-19 Vaccine Targeting SARS-CoV-2 Variant JN.1

COVID-19 Vaccine Moderna Spikevax Taiwan FDA SARS-CoV-2 JN.1

Accesswire

Published on 06/04/2026 at 21:10, 14 minutes ago

Taranis Updates Shareholders on Disbursements of Taranis Securities to Matachewan and McChip Shareholders
Published on 06/04/2026 at 18:25, 2 hours 59 minutes ago

Touchstone Exploration Inc. Proposed Fundraise of US$10 Million to US$15 Million
Published on 06/04/2026 at 14:45, 6 hours 39 minutes ago

Gedeon Richter Highlights Expanding Biosimilars Portfolio and Scientific Engagement at EULAR 2026
Published on 06/04/2026 at 14:30, 6 hours 54 minutes ago

Predictiv AI's Shift Technologies Secures Multi-Phase Commercial Contract to Digitize and Scale Middle-Mile and Last-Mile Logistics for Prompt Xpress
Published on 06/04/2026 at 14:00, 7 hours 24 minutes ago

Horizon Aircraft Appoints Richard Alexander as Chief Engineer of Certified Programs

View all ACCESSWIRE

EQS Group

Published on 06/04/2026 at 20:00, 1 hour 24 minutes ago

Notes Reduction - Results of Consent Solicitation
Published on 06/04/2026 at 19:27, 1 hour 57 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/04/2026 at 18:30, 2 hours 53 minutes ago

FROM DUPLANTIS TO PALTRINIERI, FAIR PLAY MENARINI KICKS OFF ITS 30TH EDITION
Published on 06/04/2026 at 17:57, 3 hours 26 minutes ago

EQS-Adhoc: Viscom SE raises its forecast for incoming orders in the 2026 financial year following a major contract
Published on 06/04/2026 at 17:50, 3 hours 33 minutes ago

Monport Laser Showcases Engraving Opportunities in Germany Ahead of World Cup 2026

Les Echos

Published on 06/04/2026 at 20:00, 1 hour 24 minutes ago

Schneider Electric announces the reference share price the initial conversion/exchange ratio of its €850 million new bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2034 and the results of the repurchase of the OC
Published on 06/04/2026 at 18:23, 3 hours ago

Shareholders’ Meeting and board of directors’ meeting held on June 4, 2026
Published on 06/04/2026 at 18:00, 3 hours 24 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of May 29, 2026
Published on 06/04/2026 at 17:45, 3 hours 39 minutes ago

Declaration of voting rights at the end of May 2026
Published on 06/04/2026 at 17:45, 3 hours 39 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE